AG
CBIO

Artal Group’s Crescent Biopharma CBIO Stock Holding History

Artal Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-85,891
Closed -$2.42M – 39
2024
Q2 		$2.42M Hold
85,891
– – 0.06% 74
2024
Q1 		$25.8M Hold
85,891
– – 0.66% 21
2023
Q4 		$20.3M Hold
85,891
– – 0.67% 21
2023
Q3 		$12.9M Hold
85,891
– – 0.55% 28
2023
Q2 		$14.9M Hold
85,891
– – 0.46% 32
2023
Q1 		$10.8M Buy
+85,891
New +$19.3M 0.64% 39
2018
Q3 		– Sell
-2,500
Closed -$4.03M – 112
2018
Q2 		$4.03M Sell
2,500
-750
-23% -$1.29M 0.09% 74
2018
Q1 		$5.28M Buy
3,250
+750
+30% +$1.56M 0.07% 65
2017
Q4 		$4.2M Buy
2,500
+475
+23% +$628K 0.06% 76
2017
Q3 		$2.83M Hold
2,025
– – 0.05% 83
2017
Q2 		$2.26M Buy
+2,025
New +$1.67M 0.04% 94

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Artal Group's CBIO Position: Q3 2024 in Review

Artal Group sold out of Crescent Biopharma (CBIO) in Q3 2024, closing a stake of 85,891 shares — an estimated $2.42M sold.

Artal Group first reported a position in CBIO in Q2 2017 and held it in 11 quarters. The position peaked at $25.8M in Q1 2024. 36 funds tracked by Wall St. Rank hold CBIO as of Q3 2024.

  • Artal Group reported no remaining Crescent Biopharma position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 85,891 Crescent Biopharma shares in Q3 2024, an estimated $2.42M.
  • Artal Group first reported a position in Crescent Biopharma in Q2 2017 and held it in 11 quarters.
  • Artal Group's Crescent Biopharma position peaked at $25.8M in Q1 2024.
  • 36 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.